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Abstract
 .In our mutation analyses of bilirubin UDP glycosyltransferase UGT1A1 gene, we encountered six patients with
Crigler–Najjar syndrome type II who were double homozygotes for G71R and Y486D, a patient with Gilbert’s syndrome
who was a single homozygote for G71R and six patients with Gilbert’s syndrome who were single heterozygote for G71R.
To clarify the role of each mutation in the occurrence of the two syndromes, we made four mutant expression models.
Relative UGT1A1 activity of a single homozygous model of G71R was 32.2"1.6% of normal, that of a single
homozygous model of Y486D was 7.6"0.5%, that of a double homozygous model of G71R and Y486D was 6.2"1.6%
and that of a heterozygous model of G71R was 60.2"3.5%. The decreased activities of the single homozygous model of
G71R and the double homozygous model were at an appropriate level to be diagnosed as Gilbert’s syndrome and CN-II,
respectively. The activity of a single heterozygous model of G71R was somewhat high to develop to the phenotype of
Gilbert’s syndrome, suggesting the presence of additional factors for the etiology of Gilbert’s syndrome. q 1998 Elsevier
Science B.V. All rights reserved.
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1. Introduction
Gilbert’s syndrome, first described by Gilbert and
w xLereboullet 1 in 1901, is characterized by mild
elevation of serum total bilirubin concentration ;68
.mM . The population incidence of Gilbert’s syn-
w xdrome is about 3;10% 2,3 . The hepatic bilirubin
 . UDP glycosyltransferase UGT1A1 activity mea-
.sured from liver tissue of these individuals is about
) Corresponding author. Tel.: q81-775-48-2121; fax: q81-
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w x30% of normal 4,5 . The more severe phenotype of
 .Crigler–Najjar syndrome type II CN-II , described
w xby Arias 6 , is characterized by notable elevation of
 .serum total bilirubin concentration 102;340 mM .
The hepatic UGT1A1 activity of these individuals is
w xabout 10% of normal 5,7 .
The cDNA of UGT1A1 and UGT1A1 gene encod-
w xing of the enzyme have been recently identified 8,9 ,
and there has been progress in mutation analysis of
the UGT1A1 gene in patients with Gilbert’s syndrome
and those with CN-II. In CN-II, five types of muta-
w xtions have been reported 10–14 . In three of these
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five mutations, it was shown that the mutated en-
zymes of CN-II had reduced activity in expression
w xstudies 13,14 . On the other hand, we reported six
patients with Gilbert’s syndrome who had heterozy-
w xgous missense mutations 15 . After that, we demon-
strated that the mutation of P229Q, which was de-
tected in Gilbert’s individuals, reduced the UGT1A1
w xactivity in expression study 16 . In addition to these
missense mutations as a cause of Gilbert’s syndrome,
it has been shown that there are individuals with a
homozygous insertion mutation in the TATA box
  . . w xTAA TA 7 17,18 , which resulted in reduced ex-
w xpression of UGT1A1 17 .
In our mutation analyses of patients with CN-II
and Gilbert’s syndrome, we encountered six patients
with CN-II who were double homozygotes for G71R
qY486D an allele which has both G71R and
. w xY486D, simultaneously 12,19 , a patient with
Gilbert’s syndrome who was a single homozygote for
w xG71R 20 and six patients with Gilbert’s syndrome
w xwho were a single heterozygote for G71R 21 . The
double homozygous mutation was the most abundant
in our mutation analyses of eight Japanese patients
with CN-II. But it was not clear how each mutation
contributes to the phenotypes as Gilbert’s syndrome
and CN-II. In this report, we expressed normal and
mutant UGT1A1s in COS-7 cells and clarified the
contribution of each mutation to these syndromes.
2. Materials and methods
2.1. Materials
An ExSite PCR-Based Site-directed Mutagenesis
Kit and Mammalian Transfection Kit DEAE-dextran
. method were purchased from Stratagene La Jolla,
. w14 xUSA , C UDP-glucuronic acid from Dupont-NEN
 .Wilmington, USA , and ECL Western Blotting Kit
 .from Amersham Buckinghamshire, England .
2.2. Construction of expression ˝ectors
The cDNA of human liver UGT1A1 was amplified
by PCR and inserted into pcDL expression vector, as
w xpreviously described 16 . Mutations were introduced
using the ExSite PCR-Based Site-directed Mutagene-
sis Kit. Precise instructions were followed as speci-
fied by the manual provided with the kit. Primer sets
to introduce mutations were as follows mutation
. Xpoints are indicated by underline : 5 -CAGAGCATT-
TTACACCTTGAAGAC-3X and 5X-TCTCTGATG-
X TACAACGAGGCGTCA-3 were used for G71R G
. Xto A at nucleotide 211 . 5 -GACCATTCCTTG-
GACGTGATTGGTTTCC-3X and 5X-CTGGTAC-
X CAGGTGAGGTCGTGGGCTGCG-3 for Y486D T
.to G at nucleotide 1456 . Using these primer sets,
three independent mutant versions of the cDNA in
the pcDL vector were made. They were a single
mutant of G71R, a single mutant of Y486D, and a
double mutant of G71RqY486D. Mutation sites and
other parts of the cDNAs of the UGT1A1s were
confirmed by sequencing.
2.3. Expression of cDNAs in COS-7 cells
Twenty-four hours before transfection, 6=105
COS-7 cells were seeded in 100-mm-diameter culture
plates. DNA was transfected using the Mammalian
Transfection Kit. At transfection, 340 ml of PBS
solution containing DEAE-dextran and 1.0 mg of
DNA was poured onto the culture cells. Four mutant
expression models were generated as follows: a sin-
gle homozygote for G71R, a single homozygote for
Y486D, a double homozygote for G71RqY486D
and a single heterozygote for G71R. In the heterozy-
gous model of G71R, pcDL vector with normal
 .UGT1A1 cDNA 0.5 mgrplate and pcDL vector
 .with mutated UGT1A1 cDNA 0.5 mgrplate were
co-transfected to the cells. Forty-eight hours after
transfection, these COS-7 cells were harvested and
frozen at y808C until subsequent analyses. Protein
content was measured according to the method of
w xLowry et al. 22 .
2.4. Preparation of antibody and measurement of
expressed protein
 .A peptide 37 amino acid residues was synthe-
w xsized, as described earlier 23 . A polyclonal antibody
directed against the synthetic peptide was generated
by immunizing rabbits. Immunoaffinity antibody pu-
rification was carried out by coupling 6 mg of syn-
thetic peptide to agarose gel. The final titer of puri-
fied antibody was 1:34,000.
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2.5. Western blotting
Cell homogenates were subjected to the SDS-
PAGE. The protein was transferred to Immunobilone
 .Transfer Membrane Millipore, Bedford MA . Detec-
tion was done using the ECL blotting system. The
membrane was incubated for 12 h in blocking solu-
tion, and for 8 h in a solution of anti-UGT1A1
 .antibody 1:1000 , and for 1 h in a solution of
 .anti-rabbit antibody 1:1000 . Then, the detection
solution was added and exposed to a film for 3;60
min. The relative amounts of expressed UGT1A1s
were determined from the peak areas of protein bands
measured by a densitometer, Shimadzu TCL Scanner
 .CS-910 Shimadzu, Kyoto .
2.6. Assay of UGT1A1 acti˝ity
An assay of UGT1A1 activity was performed as
w xreported earlier 24,25 , with a slight modification as
follows. The incubation mixture contained the follow-
ing: cell homogenate, unconjugated bilirubin 86
.  . mM , UDP-glucuronic acid 10 mM , 0.25 mCi 9.25
. w14 x  .kBq of C UDP-glucuronic acid 8.75 mM , bovine
 .  .serum albumin 36 mM , MgCl 10 mM , and 1002
 .mM Tris–maleate buffer pH 7.4 in a final volume
of 100 ml. Incubations were carried out at 378C for
30 min, or for a period of time indicated. The reac-
tion was terminated by adding 200 ml of ice-cold
pure alcohol. These mixtures were centrifuged at
12,000 rpm for 15 min. Supernatants were reduced to
20 ml by vacuum centrifugation. The bilirubin–
glucuronide was separated by thin layer chromatogra-
 . phy TLC of TLC plastic sheets 5748 Merck,
Fig. 1. Western blotting of expressed UGT1A1s. A total of 3 mg
of cell homogenates were subjected to the SDS-PAGE in each
lane. The peak areas of the protein bands on the film were
 . measured by a densitometer. a Mock transfection transfection
.  .of pcDL vector without cDNA , b homozygous model of
 .  .G71RqY486D, c homozygous model of Y486D, d homozy-
 .gous model of G71R, and e normal UGT1A1.
Fig. 2. Time course of UGT1A1 reaction. The amounts of
expressed cell homogenates used for the reactions were 240 mg.
Incubations were carried out for 15, 30, 60 and 120 min.
.Darmstadt . The spots containing the bilirubin–
glucuronide were measured by Molecular Imager GS
 .525 Bio-Rad, Hercules . TLC plates were also ex-
 .posed to BioMax films Kodak, Rochester for 7
days.
3. Results
3.1. Verification of UGT1A1 expression by Western
blotting
In all expression models, a 54-kDa protein band
 .was detected by western blotting Fig. 1 . The protein
band was not detected in the mock transfection. The
molecular weight of the band was almost the same as
w xthat reported 23 . Relative amounts of expressed
Fig. 3. Correlation between the velocity of UGT1A1 reaction and
amount of the expressed cell homogenate.
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UGT1A1s were computed as described in Section 2.
The relative amounts of mutated UGT1A1s were
within 0.5;1.3-fold of normal UGT1A1.
3.2. Assay conditions of UGT1A1 acti˝ity
As shown in Fig. 2, at up to 30 min, linearity of
 .reaction product bilirubin–glucuronide with time
was observed, so the velocity at 30 min incubation
was adopted as the initial velocity. Subsequent incu-
bations were carried out for 30 min. Next, the rela-
tionship between the velocity of UGT1A1 reaction
and the amount of expressed cell homogenate was
examined. When protein concentration in each assay
tube was not equalized, linearity could not be ob-
tained. Therefore, the total amounts of protein in the
assay tubes were standardized by the addition of
non-expressed cell homogenate each assay tube con-
 .  .Fig. 4. Relative activities of homozygous mutation models A and a heterozygous mutation model of G71R B . The amount of
expressed cell homogenates used for the reaction was 200 mg. The activities of UGT1A1s were normalized by the relative amounts of
expressed UGT1A1s, which were determined by Western blotting. Means"S.D. of three independent experiments are indicated. A
typical case of a spot of bilirubin–glucuronide separated by TLC is shown at the left side of the figure.
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.tained 240 mg of protein . By the correction, the
velocity of the UGT1A1 reaction became propor-
tional to the amount of expressed cell homogenate up
 .to 240 mg of protein Fig. 3 . In the following study,
200 mg of expressed cell homogenates were used for
the assay of UGT1A1 activity.
3.3. Enzyme acti˝ities of UGT1A1s with missense
mutations
The expression experiments were performed in
triplicate. The specific activity of expressed normal
UGT1A1 was 0.62"0.16 pmolrminrmg protein.
The activities of UGT1A1s were normalized by the
relative amounts of the expressed UGT1A1s. Relative
activity of a single homozygous model of G71R was
32.2"1.6% of normal, that of a single homozygous
model of Y486D was 7.6"0.5%, and that of a
double homozygous model of G71RqY486D was
6.2"1.6% and that of a heterozygous model of
 .G71R was 60.2"3.5% Fig. 4A,B .
4. Discussion
It has been reported that hepatic UGT1A1 activity
 .measured from liver tissue of CN-II is about 10%
w xof normal 5,7 , and that of Gilbert’s syndrome is
w xabout 30% of normal 4,5 . Our six patients with
CN-II, who were double homozygote for G71Rq
Y486D, were homozygote for normal TATA box
  . . w xTAA TA 6 12,19 . The patient with Gilbert’s syn-
drome, who was a single homozygote for G71R, was
 . w xalso homozygote for TAA TA 6 20 . Therefore, it
was expected that the model of a single homozygote
for G71R detected in an individual with Gilbert’s
.syndrome would have about 30% of normal activity,
and the model of double homozygote for G71Rq
 .Y486D detected in CN-II individuals would have
about 10% of normal activity in an expression study.
As we anticipated, the decreased UGT1A1 activities
of the single mutation of G71R and the double
mutation were at an appropriate level to be diagnosed
as Gilbert’s syndrome and CN-II, respectively Fig.
.4A . These findings indicate that these homozygous
mutations are the genetic cause of the two syn-
dromes. Furthermore, the reduction of UGT1A1 ac-
tivity caused by the double mutation mainly resulted
from Y486D.
In mutation analyses of patients with CN-II, geno-
w x w xtypes of R209WrR209W 10 , Q331RrQ331R 11 ,
w xG 7 1 R q Y 4 8 6 D r G 7 1 R q Y 4 8 6 D 1 2 ,
w x w xL175Qr973delG 13 and Q331Xrwild 14 have
been reported. Expression studies for those defective
enzymes showed that a homozygous model of R209W
w xhad 4.4"2% of normal activity 13 and a heterozy-
gous model of Q331X co-transfection of normal and
. w xmutated cDNAs had 6% of normal activity 14 . The
decreased activities of the two previous studies and
present experiment for G71RqY486D were enough
to cause the phenotypes of CN-II. However, in the
case of L175Qr973delG, only the L175Q allele was
expressed in vitro, and the expressed activity 38"
.2% of normal was somewhat high to be considered
w xthe cause of CN-II 13 . We think that the transcrip-
tion and translation level of both alleles as well as the
w xsubunit structure of the enzyme 14,26 should be
analyzed to fully explain the decreased activity of the
 .single heterozygote Q331Xrwild or the compound
 .heterozygote L175Qr973delG .
It has been shown that six patients with Gilbert’s
w xsyndrome had heterozygous missense mutations 15 .
On the other hand, there are patients with Gilbert’s
syndrome who had a homozygous insertion mutation
  . . w xin the TATA box TAA TA 7 17,18 . In our on-
going study of 19 Japanese patients with Gilbert’s
 .syndrome, six had homozygous TAA TA 7, six had a
heterozygous G71R, and one had a homozygous
G71R four of the remaining cases were the other
. w xheterozygous missense mutations 21 . The
 .TAA TA 7 was the most common mutation detected
in patients with Gilbert’s syndrome in studies by
w x w xBosma et al. 17 and Monaghan et al. 18 . The
reason for the discrepancies in predominant mutation
between our work and theirs can be attributed to a
racial difference between Caucasians and Asians, as
w xshown in alcohol dehydrogenase 27 . Eleven of 19
patients with Gilbert’s syndrome had mutations in the
w xcoding region in our data 21 . More than one half of
the missense mutations detected in our study of
Japanese patients was heterozygous G71R. Therefore,
it was important to clarify how much the G71R
reduced the activity of UGT1A1 in the heterozygous
state. The activity of the heterozygous model of
 .G71R 60.2"3.5% was somewhat high to develop
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 .the phenotype of Gilbert’s syndrome Fig. 4B . Addi-
tional factors might co-exist which lead to develop-
ment of Gilbert’s syndrome. One of the additional
 . w xfactors is TAA TA 7 28 . In the six heterozygotes
for G71R of our study, two cases were compound
 .heterozygote for G71R and TAA TA 7. In such cases,
the two abnormalities would contribute additionally
to development of the phenotype of Gilbert’s syn-
drome. But the other two of the six heterozygote for
 . G71R were homozygote for TAA TA 6. The re-
.maining two were not sequenced at TATA box .
Therefore, other additional factors such as occult
hemolysis may exist which lead to development of
Gilbert’s syndrome in the case of heterozygous G71R.
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